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ABSTRACT
Purpose To investigate the potential of two flow imagingmicros-
copy (FIM) techniques (Micro-Flow Imaging (MFI) and
FlowCAM) to determine total cell concentration and cell viability.
Methods B-lineage acute lymphoblastic leukemia (B-ALL)
cells of 2 different donors were exposed to ambient conditions.
Samples were taken at different days and measured with MFI,
FlowCAM, hemocytometry and automated cell counting.
Dead and live cells from a fresh B-ALL cell suspension were
fractionated by flow cytometry in order to derive software filters
based onmorphological parameters of separate cell populations
with MFI and FlowCAM. The filter sets were used to assess cell
viability in the measured samples.
Results All techniques gave fairly similar cell concentration values
over the whole incubation period. MFI showed to be superior
with respect to precision, whereas FlowCAM provided particle
images with a higher resolution. Moreover, both FIM methods
were able to provide similar results for cell viability as the conven-
tional methods (hemocytometry and automated cell counting).
Conclusion FIM-based methods may be advantageous over
conventional cell methods for determining total cell concen-
tration and cell viability, as FIMmeasures much larger sample
volumes, does not require labeling, is less laborious and pro-
vides images of individual cells.
KEY WORDS cell basedmedicinal product . cell viability .
FlowCAM . hemocytometry . micro-flow imaging . particle
analysis
ABBREVIATIONS
ABD Area based diameter
B-ALL B-lineage acute lymphoblastic leukemia
CBMPs Cell-based medicinal products
DMSO Dimethylsulfoxide
K2HPO4 Dipotassium phosphate
ECD Equivalent circular diameter
FACS Fluorescence-assisted cell sorting
FIM Flow imaging microscopy
FSC Forward scatter
HSA Human serum albumin
MFI Micro-flow imaging
MVAS MFI View analysis suite
MVSS MFI View system software
NaCl Sodium chloride
SD Standard deviation
SSC Side scatter
INTRODUCTION
Cell-based medicinal products (CBMPs) are receiving
increasing attention by the pharmaceutical industry be-
cause of their potential in treatment of a variety of
diseases, such as cancers, viral infections, and autoim-
mune disorders (1,2). Like for any other pharmaceutical
drug product, the quality of CBMPs highly determines
their safety and efficacy (3).
The safety of a CBMP depends, amongst others, on the
presence of cellular and non-cellular impurities. When a spe-
cific cell type is required for the therapy, unwanted cell pop-
ulations are considered impurities and should be tested and
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controlled. Other impurities can be related to the process of
manufacturing, for instance, traces of raw materials used, like
micro carrier beads.
Efficacy of the CBMPs is in mainly determined by cell-
specific functional properties; however the cell viability and total
concentration of the cells is also important in this. During pro-
duction, starting cell materials undergo different manipulations,
such as harvesting, purification, genetic manipulation, expan-
sion, freezing and thawing (4). These process steps, as well as
other manipulations, such as storage, transport (5,6), and prep-
aration for administration to the patient (7), can induce different
types of stresses to the cells and potentially affect cell viability.
Therefore, viability and total cell concentration are considered
important quality attributes and should be measured as in-
process control, at release and during stability testing.
There are several methods to determine cell viability and
they all have their pros and cons. Despite continuous devel-
opment of new methods for assessing cell viability,
hemocytometry (8), automatic cell counting and flow
cytometry (9) are still the most frequently applied techniques
for this purpose. The flow cytometer provides information
about cell size and granularity, respectively. Granularity level
and size has been shown to be inversely related with cell via-
bility (10). The use of fluorescent dyes or fluorescently labeled
antibodies directed against cell surface markers can aid in the
evaluation of cell type and viability. Flow cytometry is consid-
ered to be a very accurate and reproducible technique for cell
viability tests, but is also considered very laborious. The sam-
ple preparation including, e.g., labeling of the cells, can be
time-consuming and expensive, and validation of flow cyto-
metric methods has been reported to be challenging (11).
The determination of cell viability with a hemocytometer is
based on staining of the dead cells using dyes like eosin and
trypan blue (8). Hemocytometry is currently the gold standard
in clinical practice for cell counting and viability determina-
tion. Whilst being a fast method, the method can be laborious
and has certain weak points (e.g. errors originating from sam-
ple preparation; low analysis volume (0.1 μL)) that potentially
compromise the accuracy of the method. With respect to the
quantity of cell suspension measured and the laborious nature
of the method, automated cell counters could provide im-
provement, especially for routine measurements, however
the analysis volume is still low (0.4 μL). Despite the higher
throughput of the automated cell counter compared to the
hemocytometer (12).
In this regard, less laborious, inexpensive techniques that
allow for rapid and reliable counting of CBMPs would be
beneficial for improving the quality and success of CBMPs
in clinical practice. Emerging flow imaging microscopy
(FIM) techniques may fulfill these needs. In these systems the
sample flows through a flow cell where images are taken with a
high-magnification digital camera. With the help of the ded-
icated instrument software, the quantity and several
morphological parameters of the particles can be extracted
from the images (13). FIM can give valuable information
about cells, without the need for labeling, and detect small
changes in cell size and morphology which have been shown
to be related to cell viability (14,15). In addition, FIM tech-
niques are generally easy and fast to perform.
One of these FIM techniques is Micro-Flow Imaging
(MFI), which owes it popularity in this field mainly to
its user-friendliness and robust operation. The applica-
tion of MFI for cells is limited but not unexplored. For
instance, Martin et al. have used MFI to study aggrega-
tion tendency of thawed hematopoietic stem cells (16). A
recent study of Farrell and coworkers used MFI to de-
termine cell confluency on micro-carriers used in
cul ture-der ived bioreactors (17 ) . Bes ides MFI,
FlowCAM has been explored for its potential in drug
product development (18–20) and drug delivery systems
(21). Even though MFI and FlowCAM are based on the
same measurement principle, they differ in several as-
pects. The FlowCAM has a higher resolution and pro-
vides more particle parameters, whereas the MFI tends
to provide a more accurate determination of particle
concentration (20,22).
The aim of this study was to evaluate the feasibility of two
FIM techniques, i.e., MFI and FlowCAM, to determine the
total cell concentration and cell viability. In the presented
study, the two techniques are used for the characterization
of two cell lines, stored for up to 8 days under ambient con-
ditions, and compared with hemocytometry and automated
cell counting as well as with each other.
MATERIALS AND METHODS
Cell Materials
B-lineage acute lymphoblastic leukemia (B-ALL) cells were
used as model cells in this study. The cells were cultured from
two different donors (ALL-CR and ALL-CM (23); further
referred to as cell line 1 and cell line 2) and provided by the
Department of Hematology, Leiden University Medical
Center (LUMC, Leiden, the Netherlands). Cells were frozen
in 60% v/v wash medium (BioWhittaker® Iscove’s Modified
Dulbecco’s Medium (IMDM) 98.5% v/v, penicillin/
streptomycin (Lonza) 1% v/v, HSA-20% 0.5% v/v) and a
final concentration of 10% v/v HSA-20%, 10% v/v DMSO
(LUMC, Leiden, the Netherlands) at a concentration of about
1 × 107 cells/mL and stored at −80°C until the start of incu-
bation experiments. After controlled thawing, washing and
counting (using a hemocytometer), cells were suspended in
NaCl 0.9% m/v +HSA-20% 2% v/v at a concentration of
106 total cells/mL and were exposed to the stress condition
described below.
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Stress Condition
The chosen stress condition was storage at ambient conditions
(on the lab bench) for up to 8 days, during which the cells
showed a gradual and reproducible decrease in viability, as
demonstrated in a pilot experiment. The total cell concentra-
tion andmorphological parameters (see below) of each sample
were analyzed at different days by using MFI and FlowCAM.
For cell line 1 the measurements were performed on day 0, 1,
2, 4, 6 and 8. The study performed with the 2nd cell line
served as a confirmative study and therefore the measure-
ments on day 4 and 6 were not performed. In parallel, the
total cell concentration and number of viable cells in the same
samples were determined with a hemocytometer and an au-
tomated cell counter. For the data analysis of both flow imag-
ing microscopy techniques we only included particles with a
size ≥4 μm, which is the lowest detectable particle size for the
automated cell counter, according to the manufacturer.
Fluorescence-Activated Cell Sorting (FACS)
Fluorescence-activated cell sorting (FACS) on a FACSAria III
(BD Biosciences, New Jersey, USA) was used to separate dead
and/or dying cells from living cells based on the forward scat-
ter (FSC) and side scatter (SSC) ‘live gate’ as shown in
Supplementary Fig. S1. The presumably dead and live cells
that were collected with the FACS were then measured with
MFI and FlowCAM. These FIM data were used to develop
software filters for dead and live cells for each FIM technique
(see results section).
Hemocytometry
Cell suspensions were diluted twofold with a trypan blue so-
lution (0.4% (w/v) in 0.81% m/v NaCl and 0.06% m/v
K2HPO4 (Bio-Rad, Hercules, California, USA)). Ten μL of
the mixture was placed on a Bright-Line hemocytometer glass
(Sigma-Aldrich, Steinheim, Germany), and analyzed by using
a light microscope (Zeiss Axiostar Plus, Carl Zeiss Light
Microscopy, Göttingen, Germany) with 10× magnification.
Both viable (not stained) and non-viable (stained) cells were
counted in 25 frames of the hemocytometer according to the
manufacturer’s recommendations and the percentage of via-
ble cells to the total was calculated (24). For each sample
triplicate measurements were conducted.
Automated Cell Counting
Ten μL of the mixture prepared for the hemocytometry was
introduced into the counting slide. Subsequently, the total cell
concentration and percentage of viable cells were measured
by using a Bio-Rad TC20 Automated Cell Counter (Bio Rad,
Hercules, California, USA). This procedure was repeated
three times for each sample.
Micro-Flow Imaging (MFI)
In order to reduce the probability of detection of optically
overlapping particles, cell-containing samples were first dilut-
ed 4-fold with particle free NaCl 0.9% m/v +HSA-20% 2%
v/v. The diluted samples were analyzed by using a Micro-
Flow Imaging 5200 (Protein Simple, Santa Clara, CA,
USA), with MFI View System Software (MVSS) Version 2.
No software filters were applied during the runs. The 100-μm
silane coated flow cell was rinsed with flow of ultrapure water
(18.2 MΩ.cm; dispensed by using a Purelab Ultra water pu-
rification system, ELGA LabWater, Marlow, UK) and there-
after a background measurement was taken with particle free
NaCl 0.9% m/v + HSA-20% 2% v/v. For the analysis,
0.50 ml of each sample was run at a flow rate of 0.17 mL/
min. The data analysis was performed with MFI View
Analysis Suite (MVAS) Version 1.2. For the data analysis,
the lower size limit was set at 2 μm in order to avoid analysis
on the edge of the detectable particle size range (i.e., 1 μm).
The upper size limit was set at 20 μm because particles larger
than that were most likely contaminants (e.g., dust) and con-
tributed to less than 0.1% of the total particle concentration.
Table I summarizes the main morphological parameters pro-
vided by the MVAS and their descriptions. The size distribu-
tion of each sample was presented in equivalent circular di-
ameter (ECD). Each sample was measured three times with
MFI.
FlowCAM
The second flow imaging technique used in this study was a
FlowCAM VS1 (Fluid Imaging Technologies, Yarmouth,
ME, USA). After rinsing the FC50 flow cell with ultrapure
water, 100 μL of each 4-fold diluted sample was run at a flow
rate of 0.030 ml/min controlled by a C70 syringe pump.
Images were taken with a Sony XCD-SX90 camera at 22
fps (shutter: 8, gain: 224, 20× lens). The data were analyzed
by Visual SpreadSheet Version 3. For reasons described in the
MFI section, only particles between 2 and 20 μmwere includ-
ed in the data analysis. In order to remove edge particles
(particles that were detected at the borders of the camera field,
hence imaged partially), the acceptable detection field was
reduced to 95–1183 and 6–952, respectively, for left-right
and top-bottom orientations. The edge gradient parameter
provided by FlowCAM was used to exclude out-of-focus par-
ticles. The acceptable range for edge gradient was determined
in a preliminary study. In Table I, descriptions of the main
morphological parameters provided by the Visual
SpreadSheet are given. It is worth mentioning that the
FlowCAM can calculate the particle size through two different
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algorithms (described in Table I). In our study we chose to
proceed with the area based diameter (ABD), because the
principles of ABD and ECD are similar.
Definition of Software Filters to Discriminate Live
and Dead Cell Populations
Based on measurements of the FACS-sorted live and dead
particle poplulations (see above), the parameter that showed
the largest difference (ECD for MFI and ABD for FlowCAM)
between live and dead cells, was used as a primary filter. After
applying this primary filter, the changes of all the other pa-
rameters were evaluated and their threshold values could sys-
tematically be fine-tuned. At the end, the established set of
morphological filters was tested on the analyzed sorted frac-
tions and FIM-derived viability was compared to the trypan
blue-assisted values found for each cell sample (see results
section for details).
RESULTS
The two B-ALL cell lines were thawed, analyzed and then left
at ambient temperature for 8 days and analyzed at
predetermined time points, as described in materials and
methods.
Monitoring Total Cell Concentration Over
the Eight-Days Study Period
Figure 1 shows the total (live and dead) cell concentrations as
measured with all four techniques over the 8-days study peri-
od, for both investigated cell lines. The results indicate that all
the techniques gave fairly similar total cell concentrations.
FlowCAM appeared to have the lowest precision, followed
by hemocytometry, as judged by the standard deviations.
The total cell concentration of cell line 1 showed a slowly
decreasing trend over time, whereas for cell line 2 the cell
counts remained fairly stable.
Sorting and FIM Derived Morphology of Dead and Live
Cells
The fresh cell suspension of cell line 1 was analyzed
with a flow cytometer to derive an appropriate gate
for sorting dead and live cells (see Supplementary Fig.
S1). After the fractions were collected, a control trypan
blue assisted viability test of each fraction was per-
formed on the automated cell counter. From these
Table I Morphological parameters used in this study and their descriptions as provided by MVAS (MFI) and Visual SpreadSheet (FlowCAM)
Parameter Unit Description
Micro-Flow Imaging
Equivalent circular diameter (ECD) Microns The diameter of a circle occupying the same area as the particle
Intensity mean Intensity (0–1023) The average intensity of all image pixels representing the particle
Intensity standard Deviation Intensity (0–1023) The standard deviation of the intensity of all pixels representing the
particle
Circularity No units (0–1) The circumference of a circle with an equivalent area divided
by the actual perimeter of the particle
Aspect ratio No units (0–1) The ratio of the minor axis length over the major axis length
of an ellipse that has the same second-moment-area as the particle
FlowCAM
Area based diameter (ABD) Microns The diameter based on a circle with an area that is equal to that of the particle
Equivalent spherical diameter (ESD) Microns The mean value of 36 feret measurements (the perpendicular distance
between parallel tangents touching opposite sides of the particle;
VisualSpreadsheet makes
36 feret measurements for each particle, one each 5 degrees
between −90 degrees and+ 90 degrees)
Symmetry No units (0–1) A measure of the symmetry of the particle around its center; if
a particle is symmetric,
then the value is one
Aspect ratio No units (0–1) The ratio of the width (the shortest axis of the particle) and length
(the longest axis of the particle)
Circle fit No units (0–1) Deviation of the particle edge from a best-fit circle, normalized to
the zero to one range where a perfect fit has a value of one
Circularity No units (0–1) A shape parameter computed from the perimeter and the area;
a circle has a value of one (formula: (4 x π x Area) / Perimeter2)
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control measurements, it was found that the live popu-
lation contained almost 90% viable cells, whereas the
dead population contained no more than 20% viable
cells. For comparison, the viability of the unfractionated
and unstressed cell population was about 75%.
The sorted populations were measured with both
FIM techniques. Although it was difficult to see the
differences visually (Figs. 2 and 3), evaluation of differ-
ent morphological parameters for live and dead cells
showed a statistically significant difference between the
values of each listed parameter for live and dead cells,
except for the circularity values derived from MFI and
FlowCAM (Table II). The filters were constructed by
setting one value at a time starting from the most dis-
tinctive parameter until no change was observed in the
populations. Using this approach we defined software
filters based on the monitored morphological parameters
for dead and live cells, as shown in Table III.
Comparing Cell Viability Determination by FIM
Techniques, Hemocytometry and Automated Cell
Counting
With the help of the established software filters, the percentage
of viable cells, i.e., cell viability, was calculated for both cell lines
at different storage time points (Fig. 4). These percentages ob-
tained from different techniques showed similar trends for the
viability of both cell lines, i.e., a gradually decreasing viability
over incubation time. In addition, cell line 2 showed a stronger
survival at the studied incubation conditions (75% decrease in
viability after 8 days) than cell line 1 (50% decrease).
Morphological Parameters Obtained by FIM
Techniques
Both FIM techniques provide morphological parameters of the
detected particles (including cells) obtained from the individual
Fig. 1 Total cell concentration of (a) cell line 1 and (b) cell line 2 during 8 days of storage at ambient conditions measured by hemocytometry (black), automated
cell counting (red), MFI (yellow) and FlowCAM (blue). Error bars represent the standard deviation of triplicate measurements with each technique.
MFI morphology filter FACS sorted
Live Dead Live Dead
2 – 4 µm
4 – 11 µm
11 – 20 µm
Fig. 2 Representative images of particles detected by MFI in a B-ALL cell population. The left column shows the particles that were identified as dead or live cells
based on the morphological filters. The right column shows images of particles that were found in FACS-assisted sorted samples of live and dead cells. The MFI
morphological filter (for dead and live cells) uses only the size in the range between 4 and 11 μm.
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images. Representative images of individual particles detected
by the two FIM techniques are shown in Figs. 2 and 3. When
comparing these cell images derived fromMFI and FlowCAM,
it is obvious that FlowCAM has a much higher lens magnifica-
tion. The high-resolution images of FlowCAM may result in
the ability to derive more morphological parameters as
compared to MFI. Nevertheless, some of the parameters
allowed a comparison of FlowCAM with MFI. In our 8-days
study we monitored changes in all the 5 parameters listed in
Table I for the studied cells. Most of these parameters showed a
trend of a gradual change in the course of the 8-day study.
Figure 5 shows the size distribution of particles derived
from the MFI and FlowCAM analysis for both cell lines dur-
ing the 8-days incubation study. All the size distribution
graphs show that there was a decrease in the number of the
larger particles and an increase in the number of smaller par-
ticles over time. When focusing on cell line 1 (Fig. 5a, b), it is
obvious that the peak around 8 μm in the MFI-derived distri-
bution on day 0 slowly descended, while a new peak around
FlowCAM morphology filter FACS sorted
Live Dead Live Dead
2 – 4 µm
4 – 12
µm
12 – 20 
µm
Fig. 3 Representative images of particles detected by FlowCAM in a B-ALL cell population. The left column shows the particles that were identified as dead or
live cells based on the morphological filters. The right column shows images of particles that were found in FACS-assisted sorted samples of live and dead cells. The
FlowCAM morphological filter (for dead and live cells) uses only the size in the range between 4 and 12 μm.
Table II Derived Morphological Parameters (mean ± standard deviation)
Provided by MFI and FlowCAM for the Two Cell Fractions of Cell Line 1
Sorted Using FACS
Flow imaging microscopy
morphological
parameters*
Live cell
population
Dead cell
population
R2*
Micro-Flow Imaging
ECD 7.6± 2.2 μm 5.8± 1.8 μm 0.171
IntMean 546± 87 573± 81 0.026
IntSD 179± 53 173± 55 0.003
Cir 0.88± 0.06 0.88± 0.05 0
AR 0.85± 0.12 0.87± 0.10 0.008
FlowCAM
ABD 7.7± 3.0 μm 6.4± 2.6 μm 0.055
Sym 0.74± 0.19 0.69± 0.17 0.019
AR 0.82± 0.16 0.80± 0.13 0.005
CF 0.77± 0.17 0.75± 0.13 0.004
Cir 0.78± 0.17 0.78± 0.12 0
*Statistical comparison of the morphological parameters of the dead and live
cells. The comparison is derived after applying t-test with GraphPad Prism 5®.
R2 quantifies the fraction of all the variations in the samples that is accounted
for by a difference between the group means
Table III Specification of the Software Based Morphological Filters Used to
Identify Dead And Live Cells from Analysis Results of the FIM Methods
Flow imaging microscopy
morphological parameters
Filter for live cell
population
Filter for dead
cell population
Micro-Flow Imaging
ECD 7.25–11 μm 4–7.25 μm
IntMean ≤ 550 ≥ 550
IntSD ≤ 170 ≥ 170
FlowCAM
ABD 7–11 μm 4–9 μm
Sym ≥ 0.7 ≤ 0.8
AR ≥ 0.8 0.6–0.8
CF ≥ 0.7 ≤ 0.8
Cir ≥ 0.8 0.3–0.8
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6 μm arose and became apparent on day 8. For FlowCAM,
the change in the ABD size distribution was fairly similar to
the changes seen in the ECD size distribution with MFI. Fresh
cell sample showed a distinct peak at about 12 μm and over
time this peak disappeared and was replaced by relatively
broad peak at a smaller size range (around 6 μm). However,
there was also a third transient peak at about 8 μm seen, which
was already present in the fresh sample and increased after
24 h, and then diminished during the following days. MFI and
FlowCAM also showed similar trends for cell line 2, which
however showed a somewhat smaller cell size for the main
population on day 0.
For the determination of viability only the size range be-
tween 4 and 11 μm and 4–12 μm (indicated by the dotted
vertical lines in Fig. 5) were used with MFI and FlowCAM,
respectively. The lower size limit was fixed for both methods,
because the lowest detectable particle size of the automated
cell counter is 4 μm. Particles below 4 μm may consist of
fragmented cells or cell debris. Particles above 11 or 12 μm
include clustered cells or aggregates. From the size distribu-
tion graphs in Fig. 5 it is seen that the concentrations of pre-
sumably cell debris (particle size 2–4 μm) and clustered cells or
aggregates (particle size 11–20 μm for MFI and 12–20 μm for
FlowCAM) change over time. The concentration of the 2–
4 μm particles steadily increased as measured with MFI.
With FlowCAM the increase was only apparent during the
first few days. With respect to the aggregates, both FIM tech-
niques showed decreasing concentrations.
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Fig. 5 Size frequency distribution of the particles encountered in samples of cell line 1 (a, b) and cell line 2 (c, d) measured with MFI (a, c) and FlowCAM (c, d)
during 8 days of storage at ambient conditions. The size range actually used for the determination of total cell concentration and cell viability by usingmorphological
filters is indicated with the vertical dotted lines.
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Fig. 4 Cell viability determined with different analytical methods for cell line 1 at different time points during 8 days of storage at ambient conditions:
hemocytometry (black), automated cell counting (red), MFI (yellow) and FlowCAM (blue). The error bars represent standard deviations of triplicate measure-
ments with each method.
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Changes were also observed there during the 8-day study
in the other morphological parameters of both FIM tech-
niques. The details are shown in the Supplementary
Information (see Supplementary Fig. S2-S5 for both cell lines).
DISCUSSION
Viability and total cell concentrations are important quality
attributes of CBMPs. The availability of a rapid, easy and
reliable method is highly beneficial for viability measurement
of cells from starting material procurement throughout the
drug product manufacturing process including CBMP release
testing, storage, shipment and administration to the patient.
In this study we have investigated the potential of two dif-
ferent FIM techniques to assess the total cell concentration
and cell viability. For this purpose, the cells were placed at
ambient conditions for up to 8 days, because pilot studies
had shown that this is a convenient way to reproducibly obtain
changes in viability as function of time. Moreover, the chosen
conditions are relevant from a clinical perspective, as cells are
commonly kept for some time at room temperature before
administration. Our data show that both techniques can be
used to measure the concentration and the viability of cells,
yielding comparable results to those obtained with conven-
tional cell counting methods.
The FIM methods, once developed, are easy to perform
and do not require labeling of the cells before the measure-
ment (see comparison made in Table IV). These techniques
measure a relatively large sample volume (of 4-fold diluted
sample) and thus count considerably more cells than the con-
ventional methods such as hemocytometry. This ability is a
great asset for the accuracy and precision of both total cell
concentration and cell viability determinations. Another ad-
vantage of FIM lies in its ability to image individual cells and
obtain morphological characteristics of each detected cell.
Moreover, non-cellular materials (e.g., beads) can be manual-
ly removed from the data, to avoid inaccurate counting.
Furthermore, the imaging capability of especially FlowCAM
may allow the discrimination of different types of cells in a
heterogeneous cell population.
Although hemocytometry, automated cell counting, MFI
and FlowCAM are all able to provide an estimation of the
total and viable cell concentration, standard deviations pre-
sented in Fig. 1 indicate that the precision of methods with
respect to the cell concentration measurement follows this
pattern: MFI > automated cell counter > hemocytometry >
FlowCAM. For FlowCAM, the combination of the type of
flow cell and image frequencies used in our settings resulted
in a theoretical analysis efficiency of around 20%, meaning
that only 20% of the dispensed cell suspension was actually
imaged. This limitation in combination with the inability of
the analysis package in exclusion of stuck particles (i.e., parti-
cles adhered to the measurement cell) that appear in several
images from the analysis may be the most important contrib-
uting factors to the relatively low precision. Despite the larger
amount of suspension volume measured with the automated
cell counter (cf. Table IV), automated cell counting did not
offer a much better precision over hemocytometry with re-
spect to total cell concentration. This may be caused by the
Table IV Comparison of the Characteristics of the Techniques Evaluated in this Study
Characteristics Hemocytometry Automated cell
counting
FIM (MFI) FIM (FlowCAM)
General
Analyzed sample volume 0.1 μL 0.4 μL 260 μL 20 μL
Sample pretreatment Labeling; dilution if needed Labeling; dilution if needed Dilution Dilution
Analysis time per sample
(measurement + data analysis)
5 min 1 min 15 min 10 min (depends on
measurement settings)
Cell counting and viability determination
Accuracy* Moderate Moderate High Moderate
Precision$ Moderate Moderate High Low
Additional features
Non-cellular particles Discarded visually from
the cell counts
May interfere with the
cell counting
Can be removed
from the data afterwards
Can be removed from
the data afterwards
Detection of cell debris Depends on magnification
lens used
Not possible Possible Possible
Cell identification Visual identification Not possible Probable, when using
morphology
based software filters
Highly probable, when using
morphology based software filters
*Determined based on the effectively measured sample volume, extrapolation factor to final cell concentration unit (e.g., cells/mL)
$ Determined based on the outcome of our study
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interference of non-cellular material (e.g., contaminants such
as dust) with the cell counting. In contrast, MFI resulted in the
highest precision. The relatively large volume of imaged sam-
ple (more than 65 μL vs. 0.1 μL in hemocytometry), high
analysis efficiency (about 85%) and ability to remove stuck
particles (see above) may explain the pronounced perfor-
mance of MFI with respect to the total cell concentration
determinations. Moreover, the precision of hemocytometry
may be affected by the operator, since the method requires
visual counting and viability assessment based on visual dis-
crimination of the color of the cells.
Stability studies mimicking the clinical conditions of cell
preparation for administration and storage at ambient condi-
tions (i.e., in-use stability) are very important to establish
whether the cells are still viable upon administration.
Monitoring of the total cell concentration of cell line 1 over
storage time revealed a decreasing trend in total cell concen-
tration for all the methods. It is known that dying and dead
cells undergo fragmentation into smaller particles (25). These
cell debris particles are below the lower size limit of the auto-
mated cell counting (4 μm) and the lower size limit chosen for
FIM techniques, while in hemocytometry non-cellular parti-
cles are visually excluded and therefore not counted. FIM data
confirm this, as the ECD and ABD size distribution diagrams
(Fig. 5) show a clear increase in the number of particles below
4 μm over time, especially within the first 24 h of incubation.
This observation suggests that the FIM techniques are pre-
sumably able to detect and count cell fragments as well, which
may be useful for product characterization. However, it is not
easy to reliably determine morphological parameters of these
small particles, which appear as blurry dots in MFI and show
very limitedmorphological attributes in FlowCAM (Fig. 2 and
Fig. 3, respectively).
Another interesting finding from our study is that the FIM
techniques were able to detect clustered or aggregated cells. It
may be expected that clustered cells will always be not picked
up with the conventional techniques, given the low concentra-
tion of this population (Fig. 5) and low sample volume mea-
sured by these techniques. It should be noted that one cannot
exclude that some of the aggregates detected by FIM are
artefacts created by the transition of the wide tubing diameter
to the narrow flow cell, which condenses the cells in response
to spatial shrinking. However, the aggregates were also detect-
ed when more diluted samples (up to 16×) were measured
with FIM techniques. Furthermore it is shown that aggregates
are formed around decaying and dead cells (26).
Analysis of the FIM parameters revealed clear changes dur-
ing storage in the majority of the parameters highlighted in this
study, namely ECD, intensity mean, intensity SD and aspect
ratio for MFI; and ABD, symmetry, aspect ratio, and circle fit
for FlowCAM. BothMFI and FlowCAM revealed a decreasing
trend in the size (ECD and ABD, respectively) of the cells dur-
ing the storage for up to eight days under ambient conditions.
Moreover, cells at later time points (as of day 1) appeared to
have a higher intensity, a lower intensity SD and smaller aspect
ratios (see Supplementary Fig. S2 and S3). The latter, together
with lower symmetry and circle fit values, indicate that the cells
became less symmetric and more elongated in shape. All these
observations point towards a decrease in the population of live
cells and/or changes in the quality of the live cell population,
e.g., because of apoptosis. Shrinkage of cell size and changes in
cell shape are observed for dead and dying cells whose concen-
trations are expected to increase under stress (14).
Furthermore, a decrease in the intensity SD can be a sign of
disappearance of the cell organelles that contributed to varia-
tions in intensity of the image of a cell. Further investigation
revealed that upon storage at ambient temperature also within
the defined populations (e.g., live and dead cells) changes in
morphology were observed, most obviously in the FlowCAM
data. This suggests that in particular FlowCAM is able to pick
up early stages of loss in viability that may cause changes in the
transparency and shape of the cells (14).
It has to be noted that the two FIM techniques described
herein offer several other morphological parameters that
could be used in analysis of the cells. However, the combina-
tion of a high-magnification lens and a thin focus plane of the
flow cell results in substantial numbers of imaged particles that
were out of focus. These particles affect the values of a few
morphological parameters (e.g., intensity), and therefore were
not included in our study.
During the development of our FIM based methods, we
have used one type of cells, i.e., B-ALL cell lines. However,
CBMPs may contain cells with different morphological prop-
erties than B-ALL cells or contain multiple cell types (27). In
principle, one can apply the same approach to other cell types
and heterogeneous cell populations. Therefore, one needs to
develop specific software filters for each type of cells.
Our investigation shows that FIM techniques have the po-
tential to determine total cell concentration and cell viability.
This provides a strong basis for more detailed and specific
studies in order to validate FIM-based methods for a broad
range of CBMPs. The FIM techniques, just like the conven-
tional techniques, were able to detect differences in cell viabil-
ity between the two cell lines. This may be caused by the
difference in genetic background or disease status of the do-
nors. Moreover, we have shown other potentials that these
techniques can offer in characterization of CBMPs. The ca-
pability of detecting and imaging cell debris, cell aggregates
and potentially different cell types offers an excellent applica-
tion in characterization of impurities in CBMPs.
CONCLUSION
In this study we have developed label-free methods for cell
concentration and viability determination based on two
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different FIM techniques, MFI and FlowCAM. Our data sug-
gests that both methods deliver fairly similar results for total
cell concentration and cell viability as traditional methods, i.e.,
hemocytometry and the automated cell counting. Whereas
theMFI based method showed a higher precision with respect
to determination of the total cell concentration, the FlowCAM
based method provides higher-resolution images. The latter
may be useful to identify non-cellular particles and potentially
discriminate between different types of cells.
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